Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of RN0191 in adults with elevated LDL-C
NCT06132360Phase 1Completed
- Sponsor
- Rona Therapeutics
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of RN0191 in hypercholesterolemia (4 cohorts), sponsored by Rona Therapeutics. Primary endpoint: Safety and tolerability of RN0191 at 18 weeks. Started Jan 2024; status: completed.
02
Drugs
RN0191
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06132360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132360.